Late-Quarter Infuse Headwinds Blunt Medtronic’s Growth

Medtronic reported FY3Q20 orthopedic revenue of USD $775.6 million, +1.9% vs. FY3Q19. Company leadership characterized the light growth in the quarter as a surprise, largely due to customer buying patterns of Infuse bone morphogenetic protein biologic product. Customers using Infuse are drawing down inventories of the product in...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us